HLA-DR4 and DRB4 and COVID-19 vaccination-related ANCA-associated vasculitis: Correspondence.

Dear Editor,

We would like to share ideas on the publication “HLA‐DR4 and DRB4: potential risk alleles for COVID‐19 vaccination‐related ANCA‐associated vasculitis [1].” The negative effects of the vaccine and the interaction between HLA‐DR4 and DRB4 are recognized by Loo et al. It's interesting to note that evidence from real‐world experiences is needed to demonstrate the COVID‐19 vaccine's efficacy and safety for contemporary women [2]. Concerns concerning the safety of the COVID‐19 vaccine for expecting extend beyond death and include the potential for minor morbidities. The association with vasculitis is an interesting issue.

Despite the COVID‐19 vaccine's benefits, we are all concerned that it could be dangerous. It is difficult to determine the actual cause of the clinical issue in this case due to a lack of complete information on the health and immunological status of vaccination recipients prior to inoculation. Contradictory facts may cause people to reject and lose faith in immunizations. The cause of the problem could be a clinical comorbidity [3]. Additionally, a number of genetic variables, including STAT4, SERPINA1, CD226, CTLA‐4, FCGR2A, HLA‐B, HLA‐DP, HLA‐DQ, IRF5, PTPN22, RING1/RXRB, RXRB, and TLR9, have been linked to ANCA‐associated vasculitis [4] but were not examined in the current investigation. It is still too early to assess any potential harmful effects because there is not a complete record of a person's health or immune state prior to immunization.

CONFLICT OF INTEREST

The author declares there is no potential conflict of interest.